Bristol-Myers Squibb

• 10-QQ2 FY2026Impairment / charge

  Filed Jul 30

  Eliquis growth and lower U.S. rebates offset Revlimid’s generic erosion; rebate cash outflows weighed on H1 cash flow.

  • Revenue$13.0BYoY +5.7%
  • Net income$3.3BYoY +153.2%

• 8-KPositiveEarningsGuidance raised

  Filed Jul 30

  Demand for Opdivo Qvantig, Reblozyl and other Growth Portfolio drugs fueled a raised FY2026 revenue and non-GAAP EPS outlook.

• 8-KShareholder voteExecutive pay

  Filed May 8

  Shareholders approved the 2026 stock award and incentive plan and rejected an independent board chair proposal.

• 10-QQ1 FY2026RestructuringImpairment / charge

  Filed Apr 30

  Eliquis and newer drugs offset Revlimid’s generic erosion, but higher rebate and discount payments weighed on cash flow.

  • Revenue$11.5BYoY +2.6%
  • Net income$2.7BYoY +9.0%

• 8-KEarningsGuidance reaffirmed

  Filed Apr 30

  Camzyos, Breyanzi and Reblozyl growth offset Legacy Portfolio generic pressure; FY2026 revenue and non-GAAP EPS trend toward upper ends of guidance.

• 10-KFY2025MixedImpairment / charge

  Filed Feb 11

  Reblozyl, Breyanzi and Camzyos gains offset Revlimid erosion; lower acquisition charges drove the GAAP earnings rebound.

  • Revenue$48.2BYoY −0.2%
  • Net income$7.1Bvs −$8.9B year ago

• 8-KEarningsNew guidanceImpairment / charge

  Filed Feb 5

  Camzyos, Breyanzi and Reblozyl fueled Growth Portfolio gains, offsetting Legacy declines from generics and higher U.S. government rebates.

• 8-KPositiveInvestor update

  Filed Jan 12

  Growth Portfolio momentum underpins the launch strategy; 2026 admilparant and arlo-cel data will test near-term pipeline potential.

Coverage: 10-K filings filed since Feb 11, 2026; 10-Q since Apr 30, 2026; 8-K since Jan 12, 2026.

Request longer coverage

Company data: Wikidata Q266423